ORDOPIDINE

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H20FNO2S
Molecular Weight	285.378
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCN1CCC(CC1)C2=C(F)C(=CC=C2)S(C)(=O)=O

InChI

InChIKey=UKUPJASJNQDHPH-UHFFFAOYSA-N

InChI=1S/C14H20FNO2S/c1-3-16-9-7-11(8-10-16)12-5-4-6-13(14(12)15)19(2,17)18/h4-6,11H,3,7-10H2,1-2H3

HIDE SMILES / InChI

Description
Sources: https://clinicaltrials.gov/ct2/show/NCT01023282 | https://www.ncbi.nlm.nih.gov/pubmed/24817271 | https://deals.bio/search/showOpportunityDetails?asset_id=1643 | http://ggriebel.chez-alice.fr/Pub121.pdf

Ordopidine (also known as ACR-325) is a dopaminergic stabilizer that acts as dopamine D2 receptor antagonists with low affinity. Ordopidine under the development of NeuroSearch participated in phase I trials for the treatment of Parkinson's disease and bipolar disorder. Information about the current study of this drug is not available.

Originator

Approval Year

Patents

Sample Use Guides

In Vivo Use Guide

Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks

Route of Administration: Oral

Name

Type

Language

ORDOPIDINE

Official Name

English

ACR-325

Preferred Name

English

ordopidine [INN]

Common Name

English

PIPERIDINE, 1-ETHYL-4-(2-FLUORO-3-(METHYLSULFONYL)PHENYL)-

Systematic Name

English

1-ETHYL-4-(2-FLUORO-3-(METHYLSULFONYL)PHENYL)PIPERIDINE

Systematic Name

English

ACR325

Code

English

Ordopidine [WHO-DD]

Common Name

English

Code System Code Type Description

SMS_ID

300000034310